World's Best Scientists 2026 revealed!
Award Badge
Microbiology
Argentina
2026

D-Index & Metrics

Microbiology

D-Index
66
Citations
19480
World Ranking
2362
National Ranking
1

Pedro Cahn publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Pedro Cahn sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 265 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 234 scientists 205–214 publications: 208 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 309 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Pedro Cahn D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Pedro Cahn sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 112 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 123 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 94 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 66 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Microbiology in Argentina Leader Award
  • 2025 - Research.com Microbiology in Argentina Leader Award

Overview

Pedro Cahn is affiliated with the University of Buenos Aires in Argentina. Their research primarily focuses on the field of Medicine, with a strong emphasis on Infectious Diseases, Virology, Epidemiology, Emergency Medicine, and Public Health, Environmental and Occupational Health.

The scientist has contributed extensively to several main topics of work, including:

  • HIV/AIDS Research and Interventions
  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • HIV-related health complications and treatments
  • HIV, Drug Use, Sexual Risk
  • SARS-CoV-2 and COVID-19 Research
  • LGBTQ Health, Identity, and Policy

Pedro Cahn has published numerous papers in notable journals. Some of the recent publications include:

  • "Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression" (2020) in New England Journal of Medicine
  • "Mpox in people with advanced HIV infection: a global case series" (2023) in The Lancet
  • "Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial" (2021) in The Lancet
  • "Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection" (2020) in New England Journal of Medicine
  • "Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV" (2021) in Nature Communications

Frequent co-authors who have collaborated with Pedro Cahn include:

  • Omar Sued
  • María Inés Figueroa
  • María José Rolón
  • Jean-Michel Molina
  • Diego Cecchini

The scientist's research has appeared most frequently in the following publication venues:

  • Actualizaciones en Sida e Infectología
  • The Lancet HIV
  • SSRN Electronic Journal
  • New England Journal of Medicine
  • UNC Libraries

Best Publications

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy

  • Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

    F van Leth;P Phanuphak;K Ruxrungtham;E Baraldi

  • Antiretroviral Treatment of Adult HIV Infection

    Scott M. Hammer;Joseph J. Eron;Peter Reiss;Robert T. Schooley

  • Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

    Adriano Lazzarin;Thomas Campbell;Bonaventura Clotet;Margaret Johnson

  • Antiretroviral Treatment of Adult HIV Infection

    Unknown

  • Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

    Jean Michel Molina;Pedro Cahn;Beatriz Grinsztejn;Adriano Lazzarin

  • Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

    Unknown

  • Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

    Susan Swindells;Jaime-Federico Andrade-Villanueva;Gary J. Richmond;Giuliano Rizzardini

  • Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

    Pedro Cahn;Anton L Pozniak;Horacio Mingrone;Andrey Shuldyakov

  • Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

    Charles B Hicks;Pedro Cahn;David A Cooper;Sharon L Walmsley

  • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    Unknown

  • Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration

    Rami Kantor;David A Katzenstein;Brad Efron;Ana Patricia Carvalho

  • Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

    Unknown

  • Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

    Frank van Leth;Prahpan Phanuphak;Erik Stroes;Brian Gazzard

  • Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

    Robert Leo Murphy;Ian Sanne;Pedro Cahn;Praphan Phanuphak

  • Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

    Pedro Cahn;Juan Sierra Madero;José R Arribas;Andrea Antinori

  • Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

    Calvin J. Cohen;Jean-Michel Molina;Pedro Cahn;Bonaventura Clotet

  • Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.

    Xavier Saez-Llorens;Avyi Violari;Carl O. Deetz;Richard A. Rode

  • Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.

    Michael S. Saag;Pedro Cahn;François Raffi;Marcelo Wolff

  • Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

    Pedro Cahn;Jaime Andrade-Villanueva;José R Arribas;José M Gatell

  • A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).

    Daniel Podzamczer;Elena Ferrer;Ezequiel Consiglio;José Maria Gatell

  • G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate.

    Laura Rodero;Emilia Mellado;A Carolina Rodriguez;Angela Salve

  • Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme

    Catherine C McGowan;Pedro Cahn;Eduardo Gotuzzo;Denis Padgett

  • Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.

    Ulrik B.Ulrik Dragsted;Jan Gerstoft;Court Pedersen;Barry Peters

  • Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study

    Cristina Mussini;Patrizio Pezzotti;José M. Miró;Esteban Martinez

Frequent Co-Authors

Beatriz Grinsztejn
Beatriz Grinsztejn Oswaldo Cruz Foundation
Julio S. G. Montaner
Julio S. G. Montaner University of British Columbia
Jean-Michel Molina
Jean-Michel Molina Université Paris Cité
Sharon Walmsley
Sharon Walmsley University Health Network
Margaret Johnson
Margaret Johnson The Royal Free Hospital
Eduardo Gotuzzo
Eduardo Gotuzzo Instituto de Medicina Tropical Alexander von Humboldt
Anne-Mieke Vandamme
Anne-Mieke Vandamme Rega Institute for Medical Research
Jose R. Arribas
Jose R. Arribas Hospital Universitario La Paz
José M. Gatell
José M. Gatell University of Barcelona
Lynn Morris
Lynn Morris University of the Witwatersrand

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to a variety of career paths, many of which can be pursued through related online degrees. For those with unique challenges, options like degrees for felons provide accessible educational opportunities tailored to diverse backgrounds.

Healthcare roles linked to microbiology, such as becoming a functional medicine nurse practitioner, combine specialized knowledge of pathogens with patient care. Online programs supporting such careers enable students to gain essential skills remotely, balancing education with real-world demands.

Beyond clinical roles, microbiology graduates may explore allied areas like medical coding and health data management. Certified Professional Coders enjoy competitive salaries, as highlighted under cpc salary insights, making certification a valuable complement to scientific expertise.

Additionally, a health information management bachelor degree salary reflects the strong earning potential in managing health data systems, crucial to modern microbiology research and healthcare services.

Best Scientists Citing Pedro Cahn

Trending Scientists

Recently Published Articles